ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,354.50
0.84%
S&P ASX All Technology
3,873.00
-0.99%
Brent Oil
77.175
0.15%
US Dollar vs AUD
1.60529
0.07%
Bitcoin
96,426.24
-0.51%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. vTv Therapeutics Inc (VTVT)

  7. vTv Therapeutics Inc (VTVT) News

VTVT

vTv Therapeutics (VTVT)

vTv Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:VTVT
DateTimeSourceHeadlineSymbolCompany
09/12/202423:33PR Newswire (US)CANTEX PHARMACEUTICALS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR AZELIRAGON FOR THE TREATMENT OF BRAIN METASTASIS FROM BREAST CANCERNASDAQ:VTVTvTv Therapeutics Inc
07/12/202408:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
13/11/202408:43Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTVTvTv Therapeutics Inc
13/11/202408:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
26/10/202407:29Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
24/09/202406:28Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VTVTvTv Therapeutics Inc
09/08/202406:27Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
09/08/202406:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTVTvTv Therapeutics Inc
27/07/202406:17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
15/06/202406:22Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
14/06/202406:42Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
14/06/202406:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
28/05/202422:00PR Newswire (US)CANTEX PHARMACEUTICALS ANNOUNCES FOUR ABSTRACTS TO BE PRESENTED FEATURING AZELIRAGON AT 2024 ASCO ANNUAL MEETINGNASDAQ:VTVTvTv Therapeutics Inc
10/05/202406:51GlobeNewswire Inc.vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
10/05/202406:32Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VTVTvTv Therapeutics Inc
10/05/202406:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
19/03/202423:30PR Newswire (US)CANTEX PHARMACEUTICALS TO PRESENT AT 5TH ANNUAL GLIOBLASTOMA DRUG DEVELOPMENT SUMMITNASDAQ:VTVTvTv Therapeutics Inc
13/03/202423:00GlobeNewswire Inc.vTv Therapeutics Announces 2023 Fourth Quarter and Full Year Financial Results and Provides Corporate UpdateNASDAQ:VTVTvTv Therapeutics Inc
08/03/202408:47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
08/03/202406:34Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:VTVTvTv Therapeutics Inc
06/03/202411:52Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:VTVTvTv Therapeutics Inc
06/03/202400:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
05/03/202400:00GlobeNewswire Inc.vTv Therapeutics Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 DiabetesNASDAQ:VTVTvTv Therapeutics Inc
02/03/202400:00GlobeNewswire Inc.vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceNASDAQ:VTVTvTv Therapeutics Inc
01/03/202411:34Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VTVTvTv Therapeutics Inc
29/02/202401:26Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
29/02/202401:14Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:VTVTvTv Therapeutics Inc
29/02/202400:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VTVTvTv Therapeutics Inc
29/02/202400:00GlobeNewswire Inc.vTv Therapeutics Announces $51 Million Private Placement from Healthcare-focused Institutional Investors and the JDRF T1D FundNASDAQ:VTVTvTv Therapeutics Inc
23/02/202408:00PR Newswire (US)CANTEX PHARMACEUTICALS TO PARTICIPATE IN THE BIO CEO & INVESTOR CONFERENCENASDAQ:VTVTvTv Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VTVT

Your Recent History

ASX
TLS
Telstra
ASX
QBE
QBE Insurance
NYSE
MRK
Merck
ASX
XJO
S&P ASX 200
COIN
DOGEUSD
Dogecoin
NYSE
KO
Coca Cola
FX
EURAUD
Euro vs AUD
NASDAQ
TSLA
Tesla
NASDAQ
GOOGL
Alphabet
COIN
AVAXUSD
Avalanche
NASDAQ
NVDA
NVIDIA
ASX
RIO
Rio Tinto
ASX
MQG
Macquarie
ASX
XFL
S&P ASX 50
SPI
SP500
S&P 500
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads